Ovarian cancer statistics, 2018

CA Cancer Journal for Clinicians

Volumn 68, Issue 4, 2018, Pages 284-296

  Torre, Lindsey A ^a   Trabert, Britton ^b   DeSantis, Carol E ^a   Miller, Kimberly D ^a   Samimi, Goli ^b   Runowicz, Carolyn D ^c   Gaudet, Mia M ^a   Jemal, Ahmedin ^a   Siegel, Rebecca L ^a  

^a AMERICAN CANCER SOCIETY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

epidemiology; epithelial ovarian cancers; health disparities; ovarian neoplasms

Indexed keywords

AGE DISTRIBUTION; ARTICLE; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; EARLY DIAGNOSIS; ETHNIC DIFFERENCE; FAMILY ASSESSMENT; HUMAN; OVARY CANCER; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SURVIVAL RATE; TREND STUDY; UNITED STATES; ADULT; AGED; CARCINOMA; EARLY CANCER DIAGNOSIS; FEMALE; HEALTH DISPARITY; INCIDENCE; MIDDLE AGED; NON PROFIT ORGANIZATION; OVARY TUMOR; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMERICAN CANCER SOCIETY; CARCINOMA; EARLY DETECTION OF CANCER; FEMALE; HEALTH STATUS DISPARITIES; HUMANS; INCIDENCE; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; UNITED STATES;

EID: 85047663692     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21456     Document Type: Article

References (83)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7-30.
2. Howlader N, Noone AM, Krapcho M, et al. eds. SEER Cancer Statistics Review, 1975-2014. Bethesda, MD: National Cancer Institute; 2017. seer.cancer.gov/csr/1975_2014/. Accessed March 1, 2018.
3. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: North American Association of Central Cancer Registries (NAACCR) Incidence Data-Cancer in North America (CiNA) Analytic File, 1995-2014, for Expanded Races, Custom File With County, American Cancer Society Facts and Figures Projection Project (which includes data from the Centers for Disease Control and Prevention's National Program of Cancer Registries [NPCR], the Canadian Counsel of Cancer Registry's Provincial and Territorial Registries, and the National Cancer Institute's SEER Registries), certified by the NAACCR as meeting high-quality incidence data standards for the specified time periods. Bethesda, MD: National Cancer Institute; 2016.
4. Copeland G, Lake A, Firth R, et al. eds. Cancer in North America: 2010-2014. Volume One: Combined Cancer Incidence for the United States, Canada and North America. Springfield, IL: North American Association of Central Cancer Registries Inc; 2017.
5. Copeland G, Lake A, Firth R, et al. eds. Cancer in North America: 2010-2014. Volume Two: Registry-specific Cancer Incidence in the United States and Canada. Springfield, IL: North American Association of Central Cancer Registries Inc; 2017.
6. Adamo M, Dickie, L, Ruhl J. SEER Program Coding and Staging Manual 2016. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 2016.
7. World Health Organization, International Agency for Research on Cancer. International Classification of Diseases for Oncology, 3rd ed. Geneva, Switzerland: World Health Organization; 2000. codes.iarc.fr/. Accessed March 1, 2018.
8. World Health Organization. International Classification of Diseases, 10th revision. Geneva, Switzerland: World Health Organization; 2013. who.int/classifications/icd/en/. Accessed March 1, 2018.
9. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov). SEER*Stat Database: Incidence-SEER 9 Regs Research Data with Delay-Adjustment, Malignant Only, Nov 2016 Sub (1975-2014) -Linked To County Attributes-Total US, 1969-2015 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2017.
10. Surveillance, Epidemiology, and End Results (SEER) Program (seer.cancer.gov). SEER*Stat Database: Incidence-SEER 13 Regs Research Data with Delay-Adjustment, Malignant Only, Nov 2016 Sub (1992-2014) -Linked To County Attributes-Total US, 1969-2015 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2017.
11. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov). SEER*Stat Database: Incidence-SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2016 Sub (2000-2014) -Linked To County Attributes-Total US, 1969-2015 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2017.
12. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov). SEER*Stat Database: Mortality-All COD, Total US (1969-2015) -Linked To County Attributes-Total US, 1969-2015 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2017. Underlying mortality data provided by the National Center for Health Statistics (www.cdc.gov/nchs).
13. Surveillance Research Program, National Cancer Institute. SEER*Stat software (seer.cancer.gov/seerstat), version 8.3.4. Bethesda, MD: National Cancer Institute; 2017.
14. Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer Institute. Joinpoint Regression Program, version 4.5.0.1 [software program]. Bethesda, MD: National Cancer Institute; 2017.
15. Surveillance Research Program, Statistical Methodology and Applications, National Cancer Institute. DevCan: Probability of Developing or Dying of Cancer Software, version 6.7.5 [software program]. Bethesda, MD: National Cancer Institute; 2017. surveillance.cancer.gov/devcan/. Accessed March 1, 2018.
16. Cibula D, Widschwendter M, Majek O, Dusek L. Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Hum Reprod Update. 2011;17:55-67.
17. Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R, Hermon C, Peto R, Reeves G. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371:303-314.
18. Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Gaitskell K, et al. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet. 2015;385:1835-1842.
19. Wentzensen N, Poole EM, Trabert B, et al. Ovarian cancer risk factors by histologic subtype: an analysis from the Ovarian Cancer Cohort Consortium. J Clin Oncol. 2016;34:2888-2898.
20. Wu AH, Pearce CL, Tseng CC, Pike MC. African Americans and Hispanics remain at lower risk of ovarian cancer than non-Hispanic whites after considering nongenetic risk factors and oophorectomy rates. Cancer Epidemiol Biomarkers Prev. 2015;24:1094-1100.
21. Long B, Chang J, Ziogas A, Tewari KS, Anton-Culver H, Bristow RE. Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California. Am J Obstet Gynecol. 2015;212:468.e1-468e.9.
22. Bristow RE, Powell MA, Al-Hammadi N, et al. Disparities in ovarian cancer care quality and survival according to race and socioeconomic status. J Natl Cancer Inst. 2013;105:823-832.
23. Yang HP, Anderson WF, Rosenberg PS, et al. Ovarian cancer incidence trends in relation to changing patterns of menopausal hormone therapy use in the United States. J Clin Oncol. 2013;31:2146-2151.
24. Sopik V, Iqbal J, Rosen B, Narod SA. Why have ovarian cancer mortality rates declined? Part I. Incidence. Gynecol Oncol. 2015;138:741-749.
25. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov). SEER*Stat Database: Mortality-All COD, Total US (1990-2015) -Linked To County Attributes-Total US, 1969-2015 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2017. Underlying mortality data provided by the National Center for Health Statistics (www.cdc.gov/nchs).
26. National Academies of Sciences, Engineering, and Medicine. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington, DC: The National Academies Press; 2016.
27. Bray F, Loos AH, Tognazzo S, La Vecchia C. Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953-2000. Int J Cancer. 2005;113:977-990.
28. Barnholtz-Sloan JS, Schwartz AG, Qureshi F, Jacques S, Malone J, Munkarah AR. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol. 2003;189:1120-1127.
29. Kurman RJ, Shih IeM. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol. 2016;186:733-747.
30. Pearce CL, Rossing MA, Lee AW, et al. Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2013;22:880-890.
31. Prat J. New insights into ovarian cancer pathology. Ann Oncol. 2012;23(suppl 10):x111-x117.
32. Kurman RJ. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol. 2013;24(suppl 10):x16-x21.
33. Matsuno RK, Sherman ME, Visvanathan K, et al. Agreement for tumor grade of ovarian carcinoma: analysis of archival tissues from the Surveillance, Epidemiology, and End Results Residual Tissue Repository. Cancer Causes Control. 2013;24:749-757.
34. Peres LC, Cushing-Haugen KL, Kobel M, et al. Invasive epithelial ovarian cancer survival by histotype and disease stage. J Natl Cancer Inst. Apr 28 2018:djy071-djy071.
35. Coburn SB, Bray F, Sherman ME, Trabert B. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. Int J Cancer. 2017;140:2451-2460.
36. Matz M, Coleman MP, Sant M, et al. The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). Gynecol Oncol. 2017;144:405-413.
37. Peres LC, Risch H, Terry KL, et al. Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies [published online ahead of print March 23, 2018]. Int J Epidemiol. doi: 10.1093/ije/dyy054.
38. Park HK, Ruterbusch JJ, Cote ML. Recent trends in ovarian cancer incidence and relative survival in the United States by race/ethnicity and histologic subtypes. Cancer Epidemiol Biomarkers Prev. 2017;26:1511-1518.
39. Guo SW, Zilberberg MD, Hummelshoj L. Endometriosis and ovarian cancer. Lancet Oncol. 2012;13:e189-190; author reply e190.
40. Ness RB. Endometriosis and ovarian cancer: thoughts on shared pathophysiology. Am J Obstet Gynecol. 2003;189:280-294.
41. Nezhat FR, Pejovic T, Reis FM, Guo SW. The link between endometriosis and ovarian cancer: clinical implications. Int J Gynecol Cancer. 2014;24:623-628.
42. Pearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol. 2012;13:385-394.
43. Jacoby VL, Fujimoto VY, Giudice LC, Kuppermann M, Washington AE. Racial and ethnic disparities in benign gynecologic conditions and associated surgeries. Am J Obstet Gynecol. 2010;202:514-521.
44. Jones MR, Kamara D, Karlan BY, Pharoah PDP, Gayther SA. Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction. Gynecol Oncol. 2017;147:705-713.
45. Lee KR, Young RH. The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. Am J Surg Pathol. 2003;27:281-292.
46. Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Gaitskell K, et al. Ovarian cancer and smoking: individual participant meta-analysis including 28,114 women with ovarian cancer from 51 epidemiological studies. Lancet Oncol. 2012;13:946-956.
47. Liao CI, Chow S, Chen LM, Kapp DS, Mann A, Chan JK. Trends in the incidence of serous fallopian tube, ovarian, and peritoneal cancer in the US [published online ahead of print March 4, 2018]. Gynecol Oncol. doi: 10.1016/j.ygyno.2018.01.030.
48. Trabert B, Coburn SB, Mariani A, et al. Reported incidence and survival of fallopian tube carcinomas: a population-based analysis from the North American Association of Central Cancer Registries [published online ahead of print December 21, 2017]. J Natl Cancer Inst. doi: 10.1093/jnci/djx263.
49. Bandera EV, Lee VS, Rodriguez-Rodriguez L, Powell CB, Kushi LH. Racial/ethnic disparities in ovarian cancer treatment and survival. Clin Cancer Res. 2016;22:5909-5914.
50. Bristow RE, Chang J, Ziogas A, Campos B, Chavez LR, Anton-Culver H. Sociodemographic disparities in advanced ovarian cancer survival and adherence to treatment guidelines. Obstet Gynecol. 2015;125:833-842.
51. Aranda MA, McGory M, Sekeris E, Maggard M, Ko C, Zingmond DS. Do racial/ethnic disparities exist in the utilization of high-volume surgeons for women with ovarian cancer? Gynecol Oncol. 2008;111:166-172.
52. Bristow RE, Chang J, Ziogas A, Randall LM, Anton-Culver H. High-volume ovarian cancer care: survival impact and disparities in access for advanced-stage disease. Gynecol Oncol. 2014;132:403-410.
53. Fairfield KM, Murray K, LaChance JA, et al. Intraperitoneal chemotherapy among women in the Medicare population with epithelial ovarian cancer. Gynecol Oncol. 2014;134:473-477.
54. Norquist BM, Harrell MI, Brady MF, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2016;2:482-490.
55. Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30:2654-2663.
56. Ramus SJ, Song H, Dicks E, et al. Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer [serial online]. J Natl Cancer Inst. 2015;107:djv214.
57. Song H, Dicks E, Ramus SJ, et al. Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population. J Clin Oncol. 2015;33:2901-2907.
58. Heravi-Moussavi A, Anglesio MS, Cheng SW, et al. Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N Engl J Med. 2012;366:234-242.
59. Shah SP, Kobel M, Senz J, et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med. 2009;360:2719-2729.
60. Van Nieuwenhuysen E, Lambrechts S, Lambrechts D, Leunen K, Amant F, Vergote I. Genetic changes in nonepithelial ovarian cancer. Expert Rev Anticancer Ther. 2013;13:871-882.
61. Daly MB, Pilarski R, Axilbund JE, et al. Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. J Natl Compr Canc Netw. 2016;14:153-162.
62. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317:2402-2416.
63. Gabai-Kapara E, Lahad A, Kaufman B, et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci U S A. 2014;111:14205-14210.
64. US Preventive Services Task Force. Final Recommendation Statement. BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing. Rockville, MD: US Preventive Services Task Force; 2013; uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/brca-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing. Accessed March 8, 2018.
65. Finch AP, Lubinski J, Moller P, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32:1547-1553.
66. Committee on Practice Bulletins-Gynecology, Committee on Genetics, Society of Gynecologic Oncology. Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome. Obstet Gynecol. 2017;130:e110-e126.
67. Walker JL, Powell CB, Chen LM, et al. Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. Cancer. 2015;121:2108-2120.
68. Daly MB, Pilarski R, Berry M, et al. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. J Natl Compr Canc Netw. 2017;15:9-20.
69. Friebel TM, Domchek SM, Rebbeck TR. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis [serial online]. J Natl Cancer Inst. 2014;106:dju091.
70. Moorman PG, Havrilesky LJ, Gierisch JM, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol. 2013;31:4188-4198.
71. Bonadona V, Bonaiti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011;305:2304-2310.
72. Ketabi Z, Bartuma K, Bernstein I, et al. Ovarian cancer linked to Lynch syndrome typically presents as early-onset, non-serous epithelial tumors. Gynecol Oncol. 2011;121:462-465.
73. Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA. 2004;291:2705-2712.
74. Bankhead CR, Collins C, Stokes-Lampard H, et al. Identifying symptoms of ovarian cancer: a qualitative and quantitative study. BJOG. 2008;115:1008-1014.
75. Hamilton W, Peters TJ, Bankhead C, Sharp D. Risk of ovarian cancer in women with symptoms in primary care: population based case-control study [serial online]. BMJ. 2009;339:b2998.
76. Boussios S, Zarkavelis G, Seraj E, Zerdes I, Tatsi K, Pentheroudakis G. Non-epithelial ovarian cancer: elucidating uncommon gynaecological malignancies. Anticancer Res. 2016;36:5031-5042.
77. Schultz KA, Harris AK, Schneider DT, et al. Ovarian sex cord-stromal tumors. J Oncol Pract. 2016;12:940-946.
78. Pinsky PF, Yu K, Kramer BS, et al. Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up. Gynecol Oncol. 2016;143:270-275.
79. Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387:945-956.
80. Narod SA, Sopik V, Giannakeas V. Should we screen for ovarian cancer? A commentary on the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) randomized trial. Gynecol Oncol. 2016;141:191-194.
81. US Preventive Services Task Force, Grossman DC, Curry SJ, et al. Screening for ovarian cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319:588-594.
82. Berchuck A, Havrilesky LJ, Kauff ND. Is there a role for ovarian cancer screening in high-risk women? J Clin Oncol. 2017;35:1384-1386.
83. Rosenthal AN, Fraser LSM, Philpott S, et al. Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom Familial Ovarian Cancer Screening Study. J Clin Oncol. 2017;35:1411-1420.